Healthfirst Essential Plan does not cover Zepbound when it is prescribed for weight loss. The plan’s pharmacy benefits track New York’s Medicaid rules, which exclude anti-obesity drugs. The only realistic opening for coverage is a prescription written for moderate to severe obstructive sleep apnea, and even that path runs through prior authorization with strict clinical criteria.
Why Weight-Loss Use Is Excluded
The Essential Plan is a state-subsidized program sold through NY State of Health, and its drug coverage mirrors Medicaid. Federal law lets state Medicaid programs exclude drugs used for “anorexia, weight loss, or weight gain,” and New York uses that exception.1KFF. Medicaid Coverage of and Spending on GLP-1s The state’s Medicaid pharmacy program, NYRx, states plainly that “weight loss has never been a Medicaid-approved reason for covering a drug” and names Wegovy, Ozempic, Qsymia, and Mounjaro among the drugs it will not pay for when the indication is weight loss.2eMedNY. Pharmacy Benefits
That exclusion carries into the Essential Plan. A UnitedHealthcare formulary for the New York Essential Plan, effective April 2026, lists “anti-obesity agents” as a plan exclusion barred from outpatient pharmacy coverage.3UHC Provider. NY Preferred Drug List Essential Plan Healthfirst publishes its Essential Plan formulary as a downloadable document rather than a searchable list, but the state framework applies across all Essential Plan carriers in New York.4Healthfirst. Formularies
The Sleep Apnea Exception
In December 2024, the FDA approved Zepbound for a second use: treating moderate to severe obstructive sleep apnea in adults with obesity.5American Sleep Apnea Association. Zepbound for Sleep Apnea This matters legally. States can exclude weight-loss use, but under the Medicaid Drug Rebate Program they still have to cover FDA-approved drugs for other medically accepted indications, including OSA.1KFF. Medicaid Coverage of and Spending on GLP-1s
A Healthfirst Essential Plan member with a documented OSA diagnosis therefore has a reasonable basis to request Zepbound for that condition. Getting approved is another matter. Insurers apply tight utilization controls to GLP-1 drugs even for covered uses. UnitedHealthcare’s prior authorization criteria for Zepbound in OSA, for example, require a BMI of 30 or higher, a sleep study confirming moderate to severe OSA, documented failure of dietary weight-loss efforts, and either adherence to positive airway pressure therapy or a documented inability to use it.6UHC Provider. PA Non-Formulary Zepbound The patient must not have diabetes or an HgA1c above 6.5 percent, and the prescription has to come from or in consultation with a sleep specialist.
Healthfirst’s specific criteria for Zepbound in OSA are not publicly documented. Healthfirst does require prior authorization for certain medications under the Essential Plan’s medical benefit and refers providers to a separate authorization grid for details.7Healthfirst Providers. Medications Requiring Prior Authorization Under the Medical Benefit If your doctor believes Zepbound is medically necessary for sleep apnea, have the prescriber contact Healthfirst directly to confirm what the plan requires.
If Healthfirst Denies the Request
A denial is not the end. New York gives Essential Plan members both an internal appeal through the plan and an independent external appeal through the state.
Start with the internal appeal to Healthfirst, submitted within the window given in the denial notice and backed by a letter from the prescriber explaining why the drug is medically necessary.8Healthfirst. Medicare Coverage
If the plan upholds its denial, you can take the case to the New York Department of Financial Services for an external appeal. The reviewer is independent, and the decision binds both you and Healthfirst.
- File within four months of the plan’s final adverse determination.9NY DFS. File External Appeal
- Standard decisions come within 30 days; expedited appeals, where delay could jeopardize your health, are decided within 72 hours.10Justia. NY Insurance Law Section 4914
- Plans may charge up to $25 per appeal, capped at $75 per year. The fee is waived for Medicaid enrollees and anyone showing financial hardship, and refunded if the denial is overturned.9NY DFS. File External Appeal
- Submit online through the DFS portal, by email to earesponse@dfs.ny.gov, by fax at (800) 332-2729, or by mail. Questions go to (800) 400-8882.11NY Department of Health. External Appeals
Paying Out of Pocket
Essential Plan enrollment closes off most manufacturer help. Eli Lilly’s Zepbound Savings Card, which brings the cost down to between $299 and $449 per month for people with commercial insurance, excludes anyone enrolled in Medicaid, Medicare, TRICARE, or other government-funded coverage.12Eli Lilly. Zepbound Savings The Lilly Cares Foundation patient assistance program, which supplies Lilly drugs at no cost to qualifying patients, also excludes Medicaid enrollees.13Lilly Cares. Lilly Cares Application
Full self-pay is still available. Through LillyDirect, Eli Lilly sells Zepbound at monthly prices starting at $299 for the 2.5 mg dose and reaching $699 for the 10 mg through 15 mg doses without a savings card.12Eli Lilly. Zepbound Savings Those prices apply regardless of insurance, but they are a heavy monthly expense at the income levels the Essential Plan is designed for.
What Could Change
Two developments could shift Essential Plan access to Zepbound.
In Albany, Assembly Bill A9360, introduced in December 2025, would require Medicaid to cover FDA-approved GLP-1 medications for obesity, metabolic disorders, and autism-related compulsive eating behaviors. The bill remains in the Assembly Committee on Health as of mid-2026 and has not advanced.14New York State Senate. A9360 Because Essential Plan drug coverage tracks Medicaid, passage would likely open the door for Essential Plan members as well.
At the federal level, CMS launched the BALANCE model in late 2025, a voluntary program under which CMS negotiates lower GLP-1 prices with manufacturers and offers those rates to participating state Medicaid programs. State Medicaid agencies became eligible to join in May 2026, with an application deadline of July 31, 2026.15KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid Zepbound’s KwikPen formulation is included.16CMS. BALANCE Whether New York will participate, and whether participation would extend to Essential Plan members, is not yet known.